The company is operationally profitable right now, and in fact, the prospect for some significant earnings growth in 2001 and 2002 is highly likely. We upgraded our rating on Beverly to accumulate late last year when it became apparent that Medicare reimbursement rates in coming years would be much improved. But in general, we still have concerns about unit-pricing trends in the cardiology and orthopedic areas, along with the ongoing drag from foreign currency. That's a stock that we like and have an accumulate opinion on. But that opinion largely reflects our more bullish outlook on the core nursing-home operations.
Genomics is much in the news.
Unfortunately, we have not yet added CRA to our analytical coverage. But the stock is obviously one of the more exciting within the health-care industry. The issue for investors is how to value a company whose future revenue streams can't be predicted with any accuracy, but it's the type of stock to purchase as part of a broad health-care portfolio. Abbott is a company that we believe will use its highly valued stock as currency to complete some acquisitions and fill out its product pipeline, as we mentioned earlier. The company entered a turnaround mode early last year and has shown improvements in virtually every area of its operations the past six quarters.